Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study

References

1. 1.↵
   2. Pirko I,
   3. Lucchinetti CF,
   4. Sriram S, et al

   . Gray matter involvement in multiple sclerosis. Neurology 2007;68:634–42 doi:10.1212/01.wnl.0000250267.85698.7a pmid:17325269

   Abstract/FREE Full Text
2. 2.↵
   2. Eshaghi A,
   3. Marinescu RV,
   4. Young AL, et al

   . Progression of regional grey matter atrophy in multiple sclerosis. Brain 2018;141:1665–77 doi:10.1093/brain/awy088 pmid:29741648

   CrossRefPubMed
3. 3.↵
   2. Zivadinov R,
   3. Havrdová E,
   4. Bergsland N, et al

   . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831–41 doi:10.1148/radiol.13122424 pmid:23613615

   CrossRefPubMed
4. 4.↵
   2. Eshaghi A,
   3. Prados F,
   4. Brownlee WJ, et al

   ; MAGNIMS study group. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 2018;83:210–22 doi:10.1002/ana.25145 pmid:29331092

   CrossRefPubMed
5. 5.↵
   2. Schoonheim MM,
   3. Hulst HE,
   4. Brandt RB, et al

   . Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 2015;84:776–83 doi:10.1212/WNL.0000000000001285 pmid:25616483

   CrossRefPubMed
6. 6.↵
   2. Hasan KM,
   3. Halphen C,
   4. Kamali A, et al

   . Caudate nuclei volume, diffusion tensor metrics, and T(2) relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: implications for understanding gray matter degeneration. J Magn Reson Imaging 2009;29:70–77 doi:10.1002/jmri.21648 pmid:19097116

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Hannoun S,
   3. Durand-Dubief F,
   4. Confavreux C, et al

   . Diffusion tensor-MRI evidence for extra-axonal neuronal degeneration in caudate and thalamic nuclei of patients with multiple sclerosis. AJNR Am J Neuroradiol 2012;33:1363–68 doi:10.3174/ajnr.A2983 pmid:22383236

   Abstract/FREE Full Text
8. 8.↵
   2. Cavallari M,
   3. Ceccarelli A,
   4. Wang GY, et al

   . Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis. PLoS One 2014;9:e101199 doi:10.1371/journal.pone.0101199 pmid:25047083

   CrossRefPubMed
9. 9.↵
   2. Tovar-Moll F,
   3. Evangelou IE,
   4. Chiu AW, et al

   . Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T. AJNR Am J Neuroradiol 2009;30:1380–86 doi:10.3174/ajnr.A1564 pmid:19369608

   Abstract/FREE Full Text
10. 10.↵
    2. Debernard L,
    3. Melzer TR,
    4. Van Stockum S, et al

    . Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:544–51 doi:10.1136/jnnp-2013-305612 pmid:24039024

    Abstract/FREE Full Text
11. 11.↵
    2. Inglese M,
    3. Park SJ,
    4. Johnson G, et al

    . Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol 2007;64:196–202 doi:10.1001/archneur.64.2.196 pmid:17296835

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Doche E,
    3. Lecocq A,
    4. Maarouf A, et al

    . Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis. J Neuroradiol 2017;44:158–64 doi:10.1016/j.neurad.2016.10.001 pmid:27865557

    CrossRefPubMed
13. 13.↵
    2. Lapointe E,
    3. Li DK,
    4. Traboulsee AL, et al

    . What have we learned from perfusion MRI in multiple sclerosis? AJNR Am J Neuroradiol 2018;39:994–1000 doi:10.3174/ajnr.A5504 pmid:29301779

    Abstract/FREE Full Text
14. 14.↵
    2. Zivadinov R,
    3. Tavazzi E,
    4. Bergsland N, et al

    . Brain iron at quantitative MRI is associated with disability in multiple sclerosis. Radiology 2018;289:487–96 doi:10.1148/radiol.2018180136 pmid:30015589

    CrossRefPubMed
15. 15.↵
    2. Hagemeier J,
    3. Zivadinov R,
    4. Dwyer MG, et al

    . Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. Neuroimage Clin 2018;18:1007–16 doi:10.1016/j.nicl.2017.04.008 pmid:29868452

    CrossRefPubMed
16. 16.↵
    2. Burgetova A,
    3. Dusek P,
    4. Vaneckova M, et al

    . Thalamic iron differentiates primary-progressive and relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2017;38:1079–86 doi:10.3174/ajnr.A5166 pmid:28450431

    Abstract/FREE Full Text
17. 17.↵
    2. Schweser F,
    3. Raffaini Duarte Martins AL,
    4. Hagemeier J, et al

    . Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: a proposed mechanistic relationship between inflammation and oligodendrocyte vitality. Neuroimage 2018;167:438–52 doi:10.1016/j.neuroimage.2017.10.063 pmid:29097315

    CrossRefPubMed
18. 18.↵
    2. Haider L,
    3. Simeonidou C,
    4. Steinberger G, et al

    . Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry 2014;85:1386–95 doi:10.1136/jnnp-2014-307712 pmid:24899728

    Abstract/FREE Full Text
19. 19.↵
    2. Vercellino M,
    3. Masera S,
    4. Lorenzatti M, et al

    . Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009;68:489–502 doi:10.1097/NEN.0b013e3181a19a5a pmid:19525897

    CrossRefPubMed
20. 20.↵
    2. Lublin FD,
    3. Reingold SC,
    4. Cohen JA, et al

    . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–86 doi:10.1212/WNL.0000000000000560 pmid:24871874

    CrossRefPubMed
21. 21.↵
    2. Cocozza S,
    3. Canna A,
    4. Lanzillo R, et al

    . Lack of correlation between extracranial venous abnormalities and multiple sclerosis: a quantitative MRI study. Br J Radiol 2016 Jun 27:20160321. [Epub ahead of print] doi:10.1259/bjr.20160321 pmid:27282838

    CrossRefPubMed
22. 22.↵
    2. Tedeschi E,
    3. Palma G,
    4. Canna A, et al

    . In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents. Eur Radiol 2016;26:4577–84 doi:10.1007/s00330-016-4245-2 pmid:26905870

    CrossRefPubMed
23. 23.↵
    2. Polman CH,
    3. Reingold SC,
    4. Banwell B, et al

    . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Palma G,
    3. Tedeschi E,
    4. Borrelli P, et al

    . A novel multiparametric approach to 3D quantitative MRI of the brain. PLoS One 2015;10:e0134963 doi:10.1371/journal.pone.0134963 pmid:26284778

    CrossRefPubMed
25. 25.↵
    2. Borrelli P,
    3. Palma G,
    4. Tedeschi E, et al

    . Improving signal-to-noise ratio in susceptibility weighted imaging: a novel multicomponent non-local approach. PLoS One 2015;10:e0126835 doi:10.1371/journal.pone.0126835 pmid:26030293

    CrossRefPubMed
26. 26.↵
    2. Palma G,
    3. Comerci M,
    4. Alfano B, et al

    . 3D non-local means denoising via multi-GPU. In Proceedings of the 2013 Federated Conference on Computer Science and Information Systems, Kraków, Poland; September 8–11, 2013:495–98
27. 27.↵
    2. Mahad DH,
    3. Trapp BD,
    4. Lassmann H

    . Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015;14:183–93 doi:10.1016/S1474-4422(14)70256-X pmid:25772897

    CrossRefPubMed
28. 28.↵
    2. Inglese M,
    3. Adhya S,
    4. Johnson G, et al

    . Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab 2008;28:164–71 doi:10.1038/sj.jcbfm.9600504 pmid:17473851

    CrossRefPubMed
29. 29.↵
    2. Papadaki EZ,
    3. Mastorodemos VC,
    4. Amanakis EZ, et al

    . White matter and deep gray matter hemodynamic changes in multiple sclerosis patients with clinically isolated syndrome. Magn Reson Med 2012;68:1932–42 doi:10.1002/mrm.24194 pmid:22367604

    CrossRefPubMed
30. 30.↵
    2. Debernard L,
    3. Melzer TR,
    4. Alla S, et al

    . Deep grey matter MRI abnormalities and cognitive function in relapsing-remitting multiple sclerosis. Psychiatry Res 2015;234:352–61 doi:10.1016/j.pscychresns.2015.10.004 pmid:26602610

    CrossRefPubMed
31. 31.↵
    2. Mühlau M,
    3. Buck D,
    4. Förschler A, et al

    . White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Mult Scler 2013;19:1485–92 doi:10.1177/1352458513478673 pmid:23462349

    CrossRefPubMed
32. 32.↵
    2. Hametner S,
    3. Wimmer I,
    4. Haider L, et al

    . Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848–61 doi:10.1002/ana.23974 pmid:23868451

    CrossRefPubMed
33. 33.↵
    2. Minagar A,
    3. Barnett MH,
    4. Benedict RH, et al

    . The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013;80:210–19 doi:10.1212/WNL.0b013e31827b910b pmid:23296131

    Abstract/FREE Full Text